https://www.selleckchem.com/products/didox.html
95 ± 5.16 8.22 ± 6.64, =0.03 and the positive rate was also higher than that in the survivals (23.5% 12.0%, =0.012). Regarding severe COVID-19 patients, we found that high titer of anti-MDA5 Ab (≥10.0 U/mL) was more prevalent in the non-survivals (31.2% 14.0%, =0.006). Moreover, a dynamic analysis of anti-MDA5 Ab was conducted at different time-points of COVID-19, which revealed that early profiling of anti-MDA5 Ab could distinguish severe patients from those with non-severe ones. Anti-MDA5 Ab was prevalent in the COVID-19 patients and
Like
Comment
Share
